Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | GABRP | O00591 | 2/20 | 0.45 |
| ▸ | GABRD | O14764 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.45 |
| ▸ | GABRE | P78334 | 2/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30088200 | 1.00 | IMPDH2 (0.52) | IMPDH2IMPDH1GABRPGABRDGABRA1 | |
| SCHEMBL14059834 | 0.87 | IMPDH2 (0.46) | IMPDH2IMPDH1GABRPGABRDGABRA1 | |
| SCHEMBL31213264 | 0.87 | IMPDH2 (0.46) | IMPDH2IMPDH1GABRPGABRDGABRA1 | |
| SCHEMBL2233738 | 0.83 | HDAC6 (0.43) | IMPDH2IMPDH1HDAC6MAPTGPR84 | |
| SCHEMBL3517783 | 0.82 | CHEK1 (0.62) | IMPDH2IMPDH1CHEK1HDAC6MAOB | |
| SCHEMBL30354467 | 0.76 | USP2 (0.50) | RIPK1HDAC6MAPTGPR84AHR | |
| SCHEMBL3828889 | 0.76 | USP2 (0.50) | RIPK1HDAC6MAPTGPR84AHR | |
| Hydrochloric Acid SCHEMBL3824712 | 0.74 | USP2 (0.48) | RIPK1HDAC6MAPTGPR84AHR | |
| SCHEMBL8296659 | 0.72 | CYP2A6 (0.47) | IMPDH2IMPDH1GABRPGABRDGABRA1 | |
| SCHEMBL8664673 | 0.72 | PDPK1 (0.47) | IMPDH2IMPDH1HDAC6MAPTGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784404-A4 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2009-09-09 | — | — | EP | claimed |
| JP-2008511621-A | — | — | 2008-04-17 | — | — | JP | claimed |
| EP-1784404-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-05-16 | — | — | EP | claimed |
| WO-2006025716-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | claimed |
| WO-2006025717-A1 | PYRROLO[2,3-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | claimed |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4477220-A2 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-12-18 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4031547-B1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-07 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-10301284-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-05-28 | — | — | US | disclosed |
| US-10301284-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-05-28 | — | — | US | disclosed |
| US-20180297984-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-10-18 | — | — | US | disclosed |
| WO-2018011628-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-01-18 | — | — | WO | disclosed |
| EP-1784404-A4 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2009-09-09 | — | — | EP | disclosed |
| EP-1784404-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006025716-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006025717-A1 | PYRROLO[2,3-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | IMPDH2 846/4885IMPDH1 694/4885GABRP 4485/4885 |
| US-20180297984-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | IMPDH2 4642/4885IMPDH1 4418/4885GABRP 3442/4885 |
| US-12221441-B2 | Plasma kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | IMPDH2 4057/4885IMPDH1 3777/4885GABRP 2242/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | IMPDH2 4057/4885IMPDH1 3777/4885GABRP 2242/4885 |
| US-10301284-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | IMPDH2 4642/4885IMPDH1 4418/4885GABRP 3442/4885 |
| US-20230391773-A1 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF | KLKB1, KLK1, KLK5 | IMPDH2 4057/4885IMPDH1 3777/4885GABRP 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.